

www.pihealthcancerhospital.com





Revolutionary Care. Transformative Research.

<u>Protocol Title</u>: A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

## Key Inclusion criteria

1. Histologic confirmation of non-muscle invasive bladder cancer of the transitional cell carcinoma high-grade subtype (mixed histology tumors allowed if transitional cell histology is predominant histology).

a. Cohort A: Histologically confirmed CIS (with or without Ta/T1 disease)

b. Patients are eligible if the diagnostic biopsy was done within 3 months of treatment start and a cystoscopy demonstrating no resectable disease was done within 6 calendar weeks (inclusive of 48 days) of treatment start (residual CIS is acceptable; patients with T1 disease must undergo repeat resection if muscularis propria is not present in each biopsy sample). Patients with high-grade Ta and/or T1 disease should have complete resection before study treatment.

c. Upper tract imaging within 6 months prior to study entry must not be suspicious for upper tract malignancy.

- 2. Currently eligible for intravesical BCG therapy.
- 3. Age ≥ 18 years.
- 4. Performance status: ECOG performance status of 0, 1, or 2
- 5. BCG-naive disease as defined as either of the following:
  - a. Have not received prior intravesical BCG; or
  - b. Previously received BCG but stopped receiving more than 3 years before date of randomization.

## For more information please contact

## Dr. A . Venugopal

Clinical Director & HOD Medical Oncology

Senior Consultant Medical Oncologist & Hemato - Oncologist

MD (General Medicine) DM (Medical Oncology)

MRCP - SCE Medical Oncology (UK) ECMO

Mob.No: 9980707675

venugopal.arroju@picancerhospital.ai

SPOC Jaisheel Macharla DGM - Sales Mob.No: 9000412233 jaisheel.macharla@picancerhospital.ai

Pi Health Cancer Hospital (A unit of B10 Health Technologies Pvt Ltd)

Survey no. 110, Phase IV. Plot 184, HIG-B, DLF Rd, Gachibowli, Telangana 500032 Email : info@picancerhospital.ai | Phone : +91 92814 481021 | Website: www.pihealthcancerhospital.com